Schrodinger Inc - Company Profile
Powered by 
All the data and insights you need on Schrodinger Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Schrodinger Inc Strategy Report
- Understand Schrodinger Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Schrodinger Inc (Schrodinger) is a technology company that provides software solutions for drug discovery. The company offers a computational platform designed with predictive modeling, data analytics and collaboration applicable to molecular discovery. Its pipeline includes SGR-1505 (MALT1) against non-Hodgkin's lymphoma, SGR-2921 (CDC7) to treat hematological cancers and solid tumors and SGR-3515 (Wee1) for gynecological cancers LRRK2 for Neurology and SOS1 / KRAS for cancers. Schrodinger's other products include small molecule products, biological drug discovery and material science products. It provides training, documentation and support services. The company operates in the US, Germany, Japan, Ireland, the UK, India and South Korea. Schrodinger is headquartered in New York, the US.
Headquarters
United States of America
Address
1540 Broadway, 24th Floor, New York, 10036
Website
www.schrodinger.com
Telephone
1 503 2991150
No of Employees
867
Industry
Technology and Communications
Ticker Symbol & Exchange
SDGR (NASD)
Revenue (2022)
$216.7M
19.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
127.3%
(2022 vs 2021)
Market Cap*
$1.8B
Net Profit Margin (2022)
XYZ
122.8%
(2022 vs 2021)
* As of and is in US$
Schrodinger Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pipeline: | Training | Schrodinger |
| SGR-1505 (MALT1) - Non-Hodgkin's Lymphoma | Support and Documentation | LiveDesign |
| SGR-2921 (CDC7) - Hematological Cancers and Solid Tumors | BioLuminate | |
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Others | In March, the company announced the discovery of SGR-1505, its MALT1 inhibitor. |
| 2023 | Contracts/Agreements | In January, the company entered into an agreement with Otsuka Pharmaceutical and Astex Pharmaceuticals under which Schrodinger will be responsible for drug design through lead optimization and Otsuka will be responsible for all other drug discovery and clinical development activities. |
| 2022 | Contracts/Agreements | In October, the company entered into a US$425 million drug design partnership with Eli Lilly. |
Competitor Comparison
| Key Parameters | Schrodinger Inc | Halozyme Therapeutics Inc | Inspire Medical Systems Inc | Varonis Systems Inc | Zuora Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | New York | San Diego | Golden Valley | New York | Redwood City |
| State/Province | New York | California | Minnesota | New York | California |
| No. of Employees | 867 | 373 | 1,011 | 2,233 | 1,549 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Lynton | Chairman | Executive Board | 2018 | 63 |
| Ramy Farid | Director; President; Chief Executive Officer | Executive Board | 2002 | 58 |
| Geoffrey Porges | Chief Financial Officer; Executive Vice President | Senior Management | 2022 | 62 |
| Shane Brauner | Executive Vice President; Chief Information Officer | Senior Management | 2019 | - |
| Patrick Lorton | Executive Vice President; Chief Technology Officer | Senior Management | 2021 | 39 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward